Memphasys Secures Largest Felix™ Supply Deal with Monash IVF

Major Supply Deal Anchors Felix™ Commercialisation in Australia

Memphasys Limited (ASX:MEM) has signed a 12-month exclusive national supply agreement with Monash IVF Group (ASX:MVF), one of Australia's largest fertility providers, to deploy its Felix™ automated sperm selection system across Monash IVF's 22 clinics in mainland capital cities. This deal represents Memphasys' largest commercial contract for Felix™ to date, signalling a critical transition from clinical validation to scaled commercial rollout.

The agreement follows a decade-long collaboration culminating in a pivotal clinical trial completed by Monash IVF in 2025, which validated Felix™'s performance in sperm selection. With inclusion in the Australian Register of Therapeutic Goods (ARTG), Memphasys is now positioned for immediate commercial deployment nationwide.

Phased Rollout and Revenue Visibility

The rollout begins with a three-month pilot phase at two Monash IVF clinics, focusing on system implementation, staff training, and outcome data collection. Upon successful completion, the full 12-month supply agreement activates, enabling Felix™ deployment across all 22 clinics. While commercial terms remain confidential, Memphasys expects significant recurring revenue from the supply of Felix™ cartridges and consoles, supported by a quarterly ordering schedule that enhances production planning and cash flow predictability.

Monash IVF's 12,085 stimulated IVF cycles in 2025, primarily involving Intracytoplasmic Sperm Injection (ICSI), underline the scale of potential Felix™ utilisation. The partnership not only secures a substantial revenue base but also provides a world-class reference site to validate Felix™ and support expansion to other Australian and international ART providers.

Operational Readiness and Market Expansion

Memphasys confirms it has the manufacturing capacity, supply chain infrastructure, and TGA-approved quality systems to support this commercial scale-up. The company is poised to meet increasing demand as Felix™ adoption grows beyond Monash IVF’s network, with footprints already established across Europe, the Middle East, North Africa, India, Japan, and Southeast Asia.

Chair of Memphasys’ Commercialisation Committee, Marjan Mikel, emphasised the strategic significance of the deal: "Executing this agreement validates both the clinical value of Felix™ and our commercialisation strategy. Monash IVF provides a strong platform to support broader adoption across Australia and international markets." The commercial milestone follows recent contract wins in the MENA region and Southeast Asia, reflecting Memphasys’ accelerating global rollout momentum.

Clinical Validation Underpins Commercial Confidence

The Monash IVF-led clinical trial, a multi-site study completed last year, confirmed Felix™ as best-in-class for sperm selection, a key factor in assisted reproductive technology success. The trial outcomes are expected to be published soon, potentially boosting market confidence and uptake.

Australia’s IVF market, with over 60,000 fresh cycles annually, represents a strategically important commercial arena. By securing Monash IVF as an anchor customer, Memphasys gains a significant foothold in a market that could pave the way for further contracts and international expansion.